Journal of Substance Abuse Treatment
Volume 37, Issue 3 , Pages 256-265, October 2009

Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine

  • Albert Stuart Reece, M.B.B.S., F.R.A.C.G.P., F.R.C.S. (Ed.), F.R.C.S. (Glas.), M.D.

      Affiliations

    • Corresponding Author InformationSouthcity Family Medical Centre, 39 Gladstone Rd., Hillgate Hill, Queensland 4101, Australia. Tel.: +61 738444000; fax: +61 738444015.

Southcity Family Medical Centre and University of Queensland Medical School, Queensland 4101, Australia

Received 30 June 2008; received in revised form 8 February 2009; accepted 2 March 2009. published online 27 April 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Work was conducted at Southcity Family Medical Centre. This work is the work of ASR in its entirety.

 Conflicts of interest: Naltrexone implants were sold to some patients through this clinic for use in their treatment on campus.

PII: S0740-5472(09)00028-2

doi:10.1016/j.jsat.2009.03.008

Journal of Substance Abuse Treatment
Volume 37, Issue 3 , Pages 256-265, October 2009

Article Tools

* Image Usage & Resolution